Beaumont Financial Partners Llc increased its stake in Celgene Corp (CELG) by 37.37% based on its latest 2018Q1 regulatory filing with the SEC. Beaumont Financial Partners Llc bought 4,234 shares as the company’s stock declined 18.51% with the market. The institutional investor held 15,565 shares of the major pharmaceuticals company at the end of 2018Q1, valued at $1.39 million, up from 11,331 at the end of the previous reported quarter. Beaumont Financial Partners Llc who had been investing in Celgene Corp for a number of months, seems to be bullish on the $56.34B market cap company. The stock decreased 0.45% or $0.35 during the last trading session, reaching $77.73. About 5.92 million shares traded. Celgene Corporation (NASDAQ:CELG) has declined 32.65% since June 19, 2017 and is downtrending. It has underperformed by 45.22% the S&P500. Some Historical CELG News: 01/05/2018 – Keytruda sales power Merck to quarterly beat; 20/03/2018 – PROTHENA CORPORATION- COLLABORATION INCLUDES POTENTIAL LICENSE PAYMENTS, MILESTONES, PLUS ADDITIONAL ROYALTIES ON SALES FROM LICENSED PROGRAMS FOR CO; 06/04/2018 – Incyte and Merck Provide Update on Phase 3 Study of Epacadostat in Combination with KEYTRUDA® (pembrolizumab) in Patients with Unresectable or Metastatic Melanoma; 16/05/2018 – G1 Therapeutics to Present Phase 1b Data on G1T38 in Combination with Faslodex for Treatment of Breast Cancer at 2018 American; 08/05/2018 – OncoSec Expands Relationship with Merck, Announces Clinical Collaboration to Evaluate Combination of lmmunoPulse® IL-12 and KEYTRUDA® (pembrolizumab) for Triple Negative Breast Cancer; 23/04/2018 – EUROPEAN MEDICINES AGENCY VALIDATES TYPE Il VARIATION FOR MERCK’S KEYTRUDA® (PEMBROLIZUMAB) IN COMBINATION WITH PEMETREXED (ALIMTA®) AND PLATINUM CHEMOTHERAPY AS FIRST-LINE THERAPY IN METASTATIC; 26/03/2018 – Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo Four-Week Dosing Schedule for Advanced; 10/04/2018 – NOVARTIS’S AFINITOR GETS FDA OK FOR TSC PARTIAL-ONSET SEIZURES; 26/04/2018 – Bristol-Myers’ cancer drug Opdivo fuels growth, but revenue falls short; 13/04/2018 – Celgene’s Revlimid Weekly Retail Sales Fell 0.4%: Symphony
William Leland Edwards increased its stake in Align Technology Inc (ALGN) by 2.92% based on its latest 2018Q1 regulatory filing with the SEC. Palo Alto Investors Llc bought 6,200 shares as the company’s stock rose 19.49% while stock markets declined. The hedge fund run by William Leland Edwards held 218,707 shares of the health care company at the end of 2018Q1, valued at $54.92M, up from 212,507 at the end of the previous reported quarter. Palo Alto Investors Llc who had been investing in Align Technology Inc for a number of months, seems to be bullish on the $29.66B market cap company. The stock increased 2.05% or $7.44 during the last trading session, reaching $370.1. About 738,776 shares traded. Align Technology, Inc. (NASDAQ:ALGN) has risen 125.29% since June 19, 2017 and is uptrending. It has outperformed by 112.72% the S&P500. Some Historical ALGN News: 04/04/2018 – Align Technology: Invisalign First Increases Applicability to 70 % of Annual Orthodontic Case Starts Worldwide; 23/05/2018 – Align Technology Reaffirms 2Q and Fiscal 2018 Guidance; 25/04/2018 – Align Technology 1Q Rev $436.9M; 15/05/2018 – Sands Capital Management Buys 3.4% Position in Align Technology; 25/04/2018 – Align Technology Sees 2Q Rev $460M-$470M; 25/04/2018 – Align Technology Provides Update Regarding SmileDirectClub Dispute; 26/03/2018 – Hartford Growth Opportunities HLS Adds Align Technology; 01/05/2018 – 3Shape Launches Straight Talk Dental Coalition Seeking to Reinstate Interoperability between TRIOS and Align Technology’s Invis; 23/05/2018 – Align Technology Hosts 2018 Investor Day; 25/04/2018 – ALIGN SAYS SDC SEEKS TO BLOCK INVISALIGN STORE PILOT PROJECT
Since February 2, 2018, it had 2 buys, and 15 sales for $61.37 million activity. 2,250 shares were sold by Tay Julie, worth $641,250 on Friday, May 11. Saia Andrea Lynn sold 4,067 shares worth $1.27M. Olson Jennifer also sold $1.07M worth of Align Technology, Inc. (NASDAQ:ALGN) on Monday, May 7. Hockridge Stuart A had sold 4,342 shares worth $1.37M. The insider Morici John sold $796,908. 10,000 shares were sold by LACOB JOSEPH, worth $3.32M on Thursday, May 31.
More notable recent Align Technology, Inc. (NASDAQ:ALGN) news were published by: Nasdaq.com which released: “Align Technology Global Funding Awarded Towards Advancing Orthodontic and Dental Research” on June 04, 2018, also Globenewswire.com with their article: “Align Technology Hosts 2018 Investor Day” published on May 23, 2018, Seekingalpha.com published: “Best And Worst Performing Nasdaq 100 Stocks Of 2018” on May 25, 2018. More interesting news about Align Technology, Inc. (NASDAQ:ALGN) were released by: Nasdaq.com and their article: “New Research: Key Drivers of Growth for Continental Building Products, Axcelis Technologies, Nautilus Group …” published on June 18, 2018 as well as Globenewswire.com‘s news article titled: “Align Technology to Speak at Upcoming Financial Conferences” with publication date: June 06, 2018.
Among 17 analysts covering Align Technology (NASDAQ:ALGN), 14 have Buy rating, 0 Sell and 3 Hold. Therefore 82% are positive. Align Technology had 69 analyst reports since July 27, 2015 according to SRatingsIntel. Stifel Nicolaus maintained the shares of ALGN in report on Monday, September 11 with “Buy” rating. The rating was maintained by Robert W. Baird with “Buy” on Monday, September 11. As per Thursday, April 26, the company rating was maintained by Morgan Stanley. As per Wednesday, May 31, the company rating was maintained by Jefferies. As per Tuesday, October 17, the company rating was maintained by Stifel Nicolaus. The firm has “Buy” rating given on Monday, December 4 by Leerink Swann. The stock of Align Technology, Inc. (NASDAQ:ALGN) has “Overweight” rating given on Monday, May 21 by Barclays Capital. Leerink Swann maintained the stock with “Buy” rating in Friday, October 27 report. The stock of Align Technology, Inc. (NASDAQ:ALGN) has “Hold” rating given on Friday, December 8 by Deutsche Bank. The rating was maintained by Credit Suisse on Thursday, April 26 with “Outperform”.
Investors sentiment decreased to 0.86 in 2018 Q1. Its down 0.07, from 0.93 in 2017Q4. It fall, as 41 investors sold ALGN shares while 216 reduced holdings. 77 funds opened positions while 143 raised stakes. 60.14 million shares or 1.24% less from 60.90 million shares in 2017Q4 were reported. Oakbrook Invs Ltd owns 6,185 shares or 0.1% of their US portfolio. Wesbanco National Bank Incorporated accumulated 0.03% or 2,245 shares. Nomura Holdg owns 0% invested in Align Technology, Inc. (NASDAQ:ALGN) for 11,526 shares. Lincoln Corp holds 0.01% or 1,363 shares. Cumberland Prtnrs has 1,020 shares. Gulf Natl Bank (Uk) Limited has invested 0.08% in Align Technology, Inc. (NASDAQ:ALGN). The Texas-based King Luther Cap Management has invested 0.01% in Align Technology, Inc. (NASDAQ:ALGN). Moreover, First Allied Advisory Svcs has 0.01% invested in Align Technology, Inc. (NASDAQ:ALGN). Twin Tree Mgmt Limited Partnership invested in 0.05% or 24,269 shares. State Board Of Administration Of Florida Retirement System owns 111,905 shares or 0.08% of their US portfolio. Mitsubishi Ufj Trust And Bk Corporation accumulated 159,128 shares. Guggenheim Cap Ltd Liability Com invested 0.22% in Align Technology, Inc. (NASDAQ:ALGN). Mirae Asset Global Invs stated it has 126,005 shares or 0.41% of all its holdings. Parsons Capital Mngmt Ri reported 4,587 shares or 0.13% of all its holdings. Moreover, Live Your Vision Ltd has 0.02% invested in Align Technology, Inc. (NASDAQ:ALGN) for 200 shares.
Since February 8, 2018, it had 2 insider purchases, and 5 insider sales for $5.91 million activity. 3,260 shares were bought by Alles Mark J, worth $299,594 on Thursday, February 8. 9,250 shares were sold by LOUGHLIN JAMES J, worth $851,093 on Monday, March 12. KAPLAN GILLA sold $1.77M worth of stock. MARIO ERNEST had sold 13,370 shares worth $1.26M.
Among 35 analysts covering Celgene Corporation (NASDAQ:CELG), 21 have Buy rating, 1 Sell and 13 Hold. Therefore 60% are positive. Celgene Corporation has $190 highest and $83 lowest target. $127.48’s average target is 64.00% above currents $77.73 stock price. Celgene Corporation had 151 analyst reports since July 21, 2015 according to SRatingsIntel. BMO Capital Markets maintained the shares of CELG in report on Tuesday, October 17 with “Outperform” rating. The firm has “Neutral” rating given on Monday, October 23 by PiperJaffray. The rating was maintained by Robert W. Baird on Tuesday, September 19 with “Buy”. Jefferies maintained the stock with “Buy” rating in Sunday, October 15 report. Jefferies initiated Celgene Corporation (NASDAQ:CELG) on Monday, July 10 with “Buy” rating. The rating was maintained by Stifel Nicolaus with “Buy” on Friday, July 28. The rating was maintained by Mizuho with “Buy” on Monday, February 5. BMO Capital Markets maintained Celgene Corporation (NASDAQ:CELG) rating on Friday, October 27. BMO Capital Markets has “Outperform” rating and $148 target. The stock of Celgene Corporation (NASDAQ:CELG) has “Buy” rating given on Thursday, January 25 by Guggenheim. As per Tuesday, September 1, the company rating was initiated by Raymond James.
Beaumont Financial Partners Llc, which manages about $2.17B and $896.50M US Long portfolio, decreased its stake in Vanguard Index Fds (VTV) by 20,694 shares to 19,563 shares, valued at $2.02M in 2018Q1, according to the filing. It also reduced its holding in Ishares Tr (MUB) by 38,478 shares in the quarter, leaving it with 36,432 shares, and cut its stake in Select Sector Spdr Tr (XLP).
Investors sentiment decreased to 0.79 in Q1 2018. Its down 0.04, from 0.83 in 2017Q4. It worsened, as 120 investors sold CELG shares while 470 reduced holdings. 106 funds opened positions while 363 raised stakes. 513.18 million shares or 8.59% less from 561.38 million shares in 2017Q4 were reported. Prentiss Smith & invested 0.49% of its portfolio in Celgene Corporation (NASDAQ:CELG). Wellington Shields Cap Mngmt Lc reported 32,550 shares or 0.44% of all its holdings. Whalerock Point Ptnrs Llc invested in 0.52% or 18,343 shares. Ibm Retirement Fund stated it has 0.3% in Celgene Corporation (NASDAQ:CELG). Massachusetts-based Cambridge Tru has invested 0.03% in Celgene Corporation (NASDAQ:CELG). Arrowstreet Capital Partnership accumulated 6.19 million shares. Kopp Inv Advisors Limited Company owns 5,206 shares for 0.47% of their portfolio. Kcm Investment Advsrs Ltd Llc invested in 3,303 shares. Mitsubishi Ufj And Banking Corporation accumulated 1.85 million shares. Shine Advisory Inc holds 0.01% of its portfolio in Celgene Corporation (NASDAQ:CELG) for 170 shares. Alliancebernstein Lp reported 3.44M shares stake. Rnc Capital Management Lc has invested 0.03% in Celgene Corporation (NASDAQ:CELG). Washington Tru invested in 127,834 shares or 0.67% of the stock. Services Corporation has invested 0.01% in Celgene Corporation (NASDAQ:CELG). Btim Corporation holds 5,221 shares or 0.01% of its portfolio.